DAREON™-8: A study to test how well different doses of BI 764532 in addition to standard of care are tolerated by people with advanced small cell lung cancer

2023-506008-20-00 Protocol 1438-0008 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 11 Jan 2024 · Status Ongoing, recruitment ended · 5 EU/EEA countries · 15 sites · Protocol 1438-0008

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 54
Countries 5
Sites 15

Extensive-stage small cell lung carcinoma (ES-SCLC)

Key facts

Sponsor
Boehringer Ingelheim International GmbH, Boehringer Ingelheim RCV GmbH & Co. KG, Boehringer Ingelheim Espana S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
11 Jan 2024 → ongoing
Decision date (initial)
2023-12-11
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
No

External identifiers

EU CT number
2023-506008-20-00
WHO UTN
U1111-1291-5998

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Extensive-stage small cell lung carcinoma (ES-SCLC)

VersionLevelCodeTermSystem organ class
21.1 PT 10041068 Small cell lung cancer extensive stage 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Boehringer Ingelheim RCV GmbH & Co. KG

Sponsor organisation
Boehringer Ingelheim RCV GmbH & Co. KG
Address
Dr.-Boehringer-Gasse 5-11, Meidling Meidling
City
Vienna
Postcode
1121
Country
Austria

Boehringer Ingelheim Espana S.A.

Sponsor organisation
Boehringer Ingelheim Espana S.A.
Address
Carrer Prat De La Riba 50, Sant Cugat Del Valles Sant Cugat Del Valles
City
Barcelona
Postcode
08174
Country
Spain

Locations

5 EU/EEA countries · 15 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 4 2
France Ongoing, recruitment ended 12 4
Germany Authorised, recruiting 3 1
Poland Ongoing, recruitment ended 9 3
Spain Ongoing, recruitment ended 12 5
Rest of world
Switzerland, Japan, United States
14

Investigational sites

Belgium

2 sites · Ended
Algemeen Ziekenhuis Groeninge
Longziekten, President Kennedylaan 4, 8500, Kortrijk
Cliniques Universitaires Saint-Luc
Medical Oncology, Hippokrateslaan 10, Batiment 54, Sint-Lambrechts-Woluwe

France

4 sites · Ongoing, recruitment ended
Institut Bergonie
Early Phase Trials and Sarcoma Units, 229 Cours De L Argonne, 33000, Bordeaux
Hospices Civils De Lyon
Service de Pneumologie, 59 Boulevard Pinel, 69500, Bron
Les Hopitaux Universitaires De Strasbourg
Centre d’Investigation Clinique-CIC, 1 Place De L Hopital, Cs 80426, Strasbourg Cedex
Institut Gustave Roussy
Département d'Innovation Thérapeutique et d’Essais Précoces - DITEP, 114 Rue Edouard Vaillant, 94800, Villejuif

Germany

1 site · Authorised, recruiting
Justus-Liebig-Universitaet Giessen
Medizinische Klinik IV Organonkologie, Gaffkystrasse 5, 35392, Giessen

Poland

3 sites · Ongoing, recruitment ended
Instytut Centrum Zdrowia Matki Polki
Department of Oncology, Ul. Rzgowska 281/289, 93-338, Lodz
Med Polonia Sp. z o.o.
NA, Obornicka 262, 60-693, Poznan
Uniwersyteckie Centrum Kliniczne
N/A, Ul. Mariana Smoluchowskiego 17, 80-214, Gdansk

Spain

5 sites · Ongoing, recruitment ended
Hospital Clinico Universitario De Valencia
Servicio de Hematología y Oncología, Avenida Blasco Ibanez 17, 46010, Valencia
Fundacion Instituto Valenciano De Oncologia
Servicio de Oncología Médica, Calle Professor Beltran Baguena 8, 46009, Valencia
Hospital Universitario Virgen De La Macarena
Servicio de Oncología Médica, Avenida Del Doctor Fedriani 3, 41009, Sevilla
Hospital Universitario Ramon Y Cajal
Servicio de Oncología Médica, Carretera Del Colmenar Viejo Km 9 100, Por El Pardo, Madrid
Instituto De Investigacion Sanitaria Fundacion Jimenez Diaz
Unidad de Ensayos Clínicos Fase I, Calle De Isaac Peral 42 Oficinas 2a Planta Oficina 1, 28015, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2024-03-11 2024-03-29 2024-03-29 2024-03-29
France 2024-02-22 2024-07-08 2025-07-31
Germany 2024-03-21
Poland 2024-01-11 2024-02-14 2025-07-31
Spain 2024-03-06 2024-10-11 2025-07-31

Oversight and notifications

Regulatory notifications under CTR Articles 38, 52, 53, 54 and 77

Temporary halts 1 · Art. 38 CTR

Temporary halt TH-38444

Halt date
2024-07-31
Member states concerned
Germany
Publication date
2024-08-01
Reason
Study management related
Benefit-risk balance changed
No
Treatment stopped
No

Application history

7 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-08-18 Germany Acceptable
2023-12-04
2023-12-06
2 SUBSTANTIAL MODIFICATION SM-1 2023-12-22 Acceptable 2024-02-14
3 SUBSTANTIAL MODIFICATION SM-2 2024-04-26 Germany Acceptable
2024-06-10
2024-06-12
4 SUBSTANTIAL MODIFICATION SM-3 2024-10-02 Germany Acceptable
2025-01-27
2025-01-27
5 SUBSTANTIAL MODIFICATION SM-4 2025-04-25 Germany Acceptable
2025-07-31
2025-08-01
6 SUBSTANTIAL MODIFICATION SM-5 2026-03-03 Germany Acceptable
2026-04-20
2026-04-22
7 NON SUBSTANTIAL MODIFICATION NSM-1 2026-05-19 Acceptable
2026-04-20
2026-05-19